Elevation Oncology
ELEV
ELEV was delisted on the 22nd of July, 2025.
81 hedge funds and large institutions have $140M invested in Elevation Oncology in 2024 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 24 increasing their positions, 21 reducing their positions, and 12 closing their positions.
150% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 12
29% more funds holding
Funds holding: 63 → 81 (+18)
14% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 21
4.98% more ownership
Funds ownership: 90.44% → 95.41% (+5%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
38% less capital invested
Capital invested by funds: $226M → $140M (-$85.3M)
67% less call options, than puts
Call options by funds: $2K | Put options by funds: $6K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$11.1M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
+$10.7M |
| 3 |
BlackRock
New York
|
+$8.73M |
| 4 |
Morgan Stanley
New York
|
+$4.69M |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$3.34M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$6.36M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$5.76M |
| 3 |
LCM
Laurion Capital Management
New York
|
-$4.56M |
| 4 |
Millennium Management
New York
|
-$3.43M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$2.15M |
ELEV Hedge Fund Activity: Q2 2024 in Review
81 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Elevation Oncology (ELEV) for Q2 2024, worth a combined $140M — down 38% from $226M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new ELEV positions and 12 closed out — a net gain of 18 holders — while 24 added to existing stakes and 21 trimmed.
The largest buyer was Frazier Life Sciences Management, opening a new position worth an estimated $11.1M. The largest seller was Point72 Asset Management, cutting an estimated $6.36M.
- 81 institutional investors held Elevation Oncology (ELEV) as of Q2 2024, up from 63 in Q1 2024.
- Funds reported $140M of Elevation Oncology stock for Q2 2024, down 38% quarter-over-quarter.
- 30 funds opened new Elevation Oncology positions in Q2 2024 and 12 closed out, a net change of +18 holders.
- The largest Elevation Oncology buyer in Q2 2024 was Frazier Life Sciences Management, an estimated $11.1M added.
- The largest Elevation Oncology seller in Q2 2024 was Point72 Asset Management, an estimated $6.36M sold.
Based on aggregated 13F filings for Q2 2024.